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Abstract: Cannabidiol (CBD) is one of the prominent phytocannabinoids found in Cannabis
sativa, differentiating from Δ9-tetrahydrocannabinol (THC) for its non-intoxicating profile and its
antianxiety/antipsychotic effects. CBD is a multi-target drug whose anti-convulsant properties are
supposed to be independent of endocannabinoid receptor CB1 and might be related to several
underlying mechanisms, such as antagonism on the orphan GPR55 receptor, regulation of adeno-
sine tone, activation of 5HT1A receptors and modulation of calcium intracellular levels. CBD is
a lipophilic compoundwith low oral bioavailability (6%) due to poor intestinal absorption and high
first-pass metabolism. Its exposure parameters are greatly influenced by feeding status (ie, high fat-
containing meals). It is mainly metabolized by cytochrome P 450 (CYP) 3A4 and 2C19, which it
strongly inhibits. A proprietary formulation of highly purified, plant-derived CBD has been
recently licensed as an adjunctive treatment for Dravet syndrome (DS) and Lennox-Gastaut
syndrome (LGS), while it is being currently investigated in tuberous sclerosis complex. The
regulatory agencies’ approval was granted based on four pivotal double-blind, placebo-
controlled, randomized clinical trials (RCTs) on overall 154 DS patients and 396 LGS ones,
receiving CBD 10 or 20 mg/kg/day BID as active treatment. The primary endpoint (reduction in
monthly seizure frequency) was met by both CBD doses. Most patients reported adverse events
(AEs), generally from mild to moderate and transient, which mainly consisted of somnolence,
sedation, decreased appetite, diarrhea and elevation in aminotransferase levels, the last being
documented only in subjects on concomitant valproate therapy. The interaction between CBD
and clobazam, likely due to CYP2C19 inhibition, might contribute to some AEs, especially
somnolence, but also to CBD clinical effectiveness. Cannabidivarin (CBDV), the propyl analogue
of CBD, showed anti-convulsant properties in pre-clinical studies, but a plant-derived, purified
proprietary formulation of CBDV recently failed the Phase II RCT in patients with uncontrolled
focal seizures.
Keywords: cannabidiol, cannabidivarin, phytocannabinoids, epileptic encephalopathies,
tuberous sclerosis complex, drug-resistance
Introduction
In June 2018, the US Food and Drug Administration (FDA) approved
a pharmaceutical preparation of highly purified, plant-derived cannabidiol (CBD)
(Epidiolex®, GW Pharmaceuticals, Cambridge, UK) for the treatment of Dravet
syndrome (DS) and Lennox-Gastaut syndrome (LGS).1 Despite the later rejection
coming from the UK National Institute for Health and Care Excellence (NICE) based
on concerns about paucity of long-term studies and economic issues,2 in
September 2019 the European Medicine Agency (EMA) granted the approval of
CBD (under the trade name of Epidyolex®) as adjunctive treatment for DS and LGS
in combination with clobazam (CLB).3 The recent decisions of the regulatory
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authorities might mark the end of an era of 'much ado' about
the use of medical cannabis in the field of epilepsy. Indeed,
after decades of legislative restrictions, in the
2010s cannabis potentialities as anti-epileptic medication
gained the media attention in the wake of some remarkable
cases,4 which paved the way to an international parent-
driven quest for CBD-enriched cannabis preparations to
treat childhood-onset refractory epilepsies. Such phenom-
enon further piqued the interest of the scientific community
for the therapeutic applications of cannabis derivatives, as
clearly demonstrated by the abrupt surge of publications on
medical cannabis (which had a 9-fold increase from 2000 to
2017), especially in the fields of psychiatry, oncology and
neurology.5 Although CBD, the best-characterized phyto-
cannabinoid (pCB) along with Δ9-tetrahydrocannabinol
(Δ9-THC), was soon singled out as a potential anticonvul-
sant compound based on both preclinical studies6 and the
favorable lack of intoxicating effects, initial supporting
evidence mostly came from low-quality studies: in fact, in
2012 and 2014 two Cochrane reviews stated that no reliable
conclusions could be drawn on cannabinoid effectiveness in
epilepsy treatment.7,8 During the following years, three
sponsored randomized clinical trials (RCTs) proved CBD
to be effective and tolerable in patients suffering from DS
and LGS, whereas its use in epileptic subjects with
Tuberous Sclerosis Complex (TSC) is currently under
investigation.
In this review, we focused on the pharmacology of CBD
and the most solid clinical evidence supporting its use as an
anti-seizure medication. We also briefly outlined the current
knowledge on cannabidivarin (CBDV) and its therapeutic
perspectives in the field of epilepsy. Relevant studies were
identified through a literature search of PubMed and the
Cochrane databases. RCTs and meta-analysis were mostly
considered during the search, and only a few open-label
studies were included. Several key-phrases such as “phytocan-
nabinoids”, “endocannabinoids”, “cannabis and epilepsy”,
“cannabinoids and epilepsy”, “cannabidiol”, “cannabidiol
and epilepsy”, “cannabidivarin”, “cannabidivarin and epi-
lepsy” were used.
Phytocannabinoids and
Endocannabinoids: A Brief
Overview
The therapeutic potentialities of cannabis plant have been
known for millennia: its medical applications were first
documented in ancient Chinese books, and over the
centuries, cannabis extracts have been used for their anti-
emetic, anti-inflammatory, analgesic and anti-convulsant
properties.9 Cannabis sativa contains around 540 natural
compounds, including over 100 pCBs. pCBs are lipids with
a common chemical structure – containing alkylresorcinol
and monoterpenes – produced by the flowering tops of the
female plant of C. sativa and released in its resin.9 They are
synthesized as acids and then decarboxylated to their neu-
tral form when dried, heated or exposed to light. Δ9-THC
and CBD are the most abundant pCBs, and share a common
precursor, cannabigerol, and similar chemical properties
(they are both C21 terpenophenolic compounds with pentyl
side-chains).10 Their propyl analogues, derived from can-
nabigerovarin, are Δ9-tetrahydrocannabivarin and CBDV,
respectively.10 Decades after the isolation of Δ9-THC by
Mechoulam in 1964,11 specific cannabinoid G protein-
coupled receptors, namely, CB1 and CB2, were eventually
cloned.12,13 CB1, which appears to be responsible for the
psychoactive effects of THC, is mainly found in the central
nervous system (CNS), especially in hippocampus, basal
ganglia and cerebellum (and, to a lesser extent, in thalamus
and lower brainstem), where it is located pre-synaptically in
both excitatory and inhibitory synapses. Conversely, CB2 is
confined to the peripheral nervous system and the immune
system cells, which might explain the anti–inflammatory
properties of cannabinoids.9 The cloning of CB1 and CB2
paved the way to the discovery of their endogenous ligands,
so-called endocannabinoids, chemically related to pCBs,
among which anandamide (AEA, from the Sanskrit word
'ananda', that means bliss)14 and 2-arachydonoyl glycerol
(2-AG) appear the most relevant. The endocannabinoid
system (ECS) seems to exert a homeostatic function and is
thought to be involved in manifold physiological processes
(“rest, eat, sleep, forget and protect”);15 therefore, its altera-
tion might be correlated with several neurological diseases
as well. The presentation of the complex endocannabinoid
signaling is far beyond the aim of this review; nevertheless,
some points should be briefly mentioned due to their possi-
ble link with epilepsy. Growing evidence suggests that ECS
might play a crucial role in modulating neuronal excitability
by dynamically regulating neurotransmitter release at the
synaptic level. Endocannabinoids are retrograde messen-
gers, synthesized “on demand” in case of increased neuro-
nal activity, probably thanks to the contribution of group 1
metabotropic glutamate receptors (mGluRs). Indeed, in
excitatory synapses, mGlu5Rs, that are typically located
peri-synaptically, are activated by glutamate (Glut) “spill
over” occurring during hyper-excitable states (like epileptic
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seizures), so producing a feed-forward mechanism.16 After
Glut binding, mGlu5Rs (coupled with Gq/11 proteins) acti-
vate phospholipase C β (PLCβ), which catalyzes the synth-
esis of diacylglycerol (DAG), a second messenger and
precursor of 2-AG. When high levels of DAG are available,
the enzyme diacylglycerol lipase α (DGLα) converts DAG
into 2-AG, which migrates in a retrograde way to the pre-
synaptic membrane.16,17 Interestingly, mGlu5Rs, PLCβ and
DGLα are all anchored together and structurally organized
by HOMER, a scaffold protein, forming a supramolecular
complex called “2-AG signalome”.16 When 2-AG binds
pre-synaptic CB1 (coupled with Gi/o), its activation triggers
various molecular pathways, including the inhibition of
adenylate cyclase and of voltage-gated calcium channels
(VGCC), which determines the decrease of Ca2+ intracel-
lular levels at the presynaptic terminal, resulting in neuro-
transmitter (Glut) release reduction.16,17 In one word, the
depolarization-induced synthesis of endocannabinoids
eventually produces a dampening in neuronal excitability,
according to the so-called “synaptic circuit-breaker model”,
and might, therefore, be protective against states of hyper-
excitability (Figure 1).17 However, CB1 receptors are
present not only on excitatory neurons but also on gamma-
aminobutyric acid (GABA)-ergic ones, where they are even
more abundant and able to produce a depolarization-
induced suppression of inhibition. Nevertheless, it has
been hypothesized (and partly demonstrated) that
a proportion of CB1 receptors on inhibitory interneurons
could represent an inactive reservoir, that not all
GABAergic cells express CB1, and that CB1 coupling
with G proteins could be less effective in GABAergic than
in glutamatergic neurons.17 Therefore, CB1-sensitive exci-
tatory synapses are supposed to exceed the inhibitory ones.
This would partly account for the possible differential
effects of THC, which has been hypothesized to exert an
anti-convulsant action at low doses and a pro-convulsant
Figure 1 Endocannabinoid-mediated negative feedback in epilepsy: (1) in excitatory synapses, depolarization induces Glutamate (Glut) release into the synaptic cleft, thanks
to the increase in intracellular Ca2+ levels mediated by the opening of voltage-gated calcium channels (VGCC); (2) in hyperexcitable states, like epileptic seizures, a large
amount of neurotransmitter is released from the presynaptic neuron; (3) under basal conditions, Glut binds primarily to intra-synaptic ionotropic receptors (AMPARs); (4) in
case of hyperexcitability with Glut “spill over”, group 1 metabotropic Glut receptors (ie, mGlu5Rs) located at pery-synpatic level are activated by ligand binding; (5)
mGLU5Rs are anchored together with phospholipase C β (PLCβ) and diacylglycerol lipase α (DGLα) thanks to the scaffolding protein HOMER, forming a sopramolecular
complex known as “2-AG signalosome” (illustrated in the smaller panel); (6) mGlu5R activation increases diacyl glycerol (DAG) synthesis by PLCβ and its following
conversion into 2-arachydonoyl glycerol (2-AG), catalyzed by DGLα; (7) 2-AG acts as a retrograde messenger and binds pre-synaptic CB1 (coupled with Gi/o); (8) CB1
activation inhibits VGCC thus reducing intracellular Ca2+ levels; (9) ↓ Ca2+ levels determine a decrease in Glut exocytosis. This negative feedback mechanism could be
protective against Glut-mediated excitotoxicity in hyperexcitable states.
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effect at higher concentrations,18 although the latter has
been shown only in few animal studies. It would also
explain why in mice not expressing CB1 (CB1
−/-), that
typically develop an epileptic phenotype, kainic-induced
status epilepticus (SE) is rescued by the selective reintro-
duction of CB1 receptors on glutamatergic synapses
alone.18
Pharmacodynamic Properties of CBD
The pharmacodynamics of CBD is extremely complex, and
only partly elucidated at present. Several putative targets have
been identified so far; still, the specific mechanisms of action
underlying CBD anti-convulsant effects are not fully clarified,
although they are currently supposed to be CB1/CB2-
independent. Indeed, CBD has such a low affinity for both
cannabinoid receptors that high concentrations (in the micro-
molar range) are necessary to displace CB1 synthetic
ligands.15,19 Nevertheless, CBD can antagonize CB1 action
at nanomolar concentrations (lower than those required to
significantly interact with the receptor orthosteric site), an
unexpected finding suggesting that it may represent an
“inverse agonist”.19 Its action as a negative allosteric modu-
lator at CB1 at concentrations <1μMwas also demonstrated in
a recent in vitro work showing reduced orthosteric ligand
(THC and 2-AG) efficacy and negative co-operativity as
a result of CBD treatment.20 However, further studies have
supported the hypothesis that mechanisms other than CB1
binding are likely to underlie CBD non-competitive
antagonism.15,19
In 2007 Ryberg et al identified the orphan G protein-
coupled receptor GPR55 as a novel target for CBD and
endocannabinoids as well.21 GPR55 is located in excita-
tory axonal terminals and is thought to facilitate Glut
release via intracellular Ca2+ level modulation in an activ-
ity-dependent way, probably contributing to short-term
potentiation in the hippocampus.9,17 CBD has been proved
to act as GPR55 antagonist, thus dampening neuronal
excitability by reducing Glut exocytosis.22 Considering
that this signaling pathway is not active at baseline condi-
tions, CBD-GPR55 interaction could represent one of the
mechanisms underlying CBD anti-convulsant effect, and
a potentially safe therapeutic target.22
Another important action of CBD – with respect to
epilepsy – is the regulation of the levels of adenosine,
a ubiquitous CNS neuromodulator hypothesized to play
a role in seizure termination, thanks to CBD-mediated
block of the equilibrative nucleotide transporter (ENT),
resulting in the inhibition of adenosine re-uptake (and
clearance) by astrocytes.23 The elevation of adenosine
tone could activate presynaptic A1 receptors (A1Rs), with
consequent reduction of Glut release from excitatory term-
inals. On the other hand, A1Rs have been demonstrated to
interact with CB1,
24 therefore extracellular adenosine
levels might indirectly modulate CB1-dependent glutama-
tergic inhibition. Moreover, CBD has been also shown to
interact with A2A receptors, which could contribute to its
anti–inflammatory and neuroprotective action.15,22,23
In spite of CBD low binding affinity (in the micromolar
range), relevant targets for its anti-convulsant effect might be
5HT receptors, in particular 5HT1A, that is coupled with Gi/o
proteins, and reduces neurotransmitter release.22 Moreover,
the modulation of GABAergic transmission as a possible
mechanism underlying CBD anti-seizure action has also
been suggested by few in vitro studies, performed on
human recombinant receptors as well as DS and TSC brain
tissues, which demonstrated CBD (at low concentrations) to
act as a positive allosteric modulator of GABAA receptors,
likely on a different site than benzodiazepines (independent
of the presence of γ subunit).25,26
In addition to this, voltage-gated sodium channels
(VGSC) have been recently proposed as potential targets
for endocannabinoids and pCBs as well: indeed, CBD has
been proved to inhibit human Nav1.1.-1.7 currents at ther-
apeutically relevant concentrations;27 moreover, in vitro
and in vivo studies have shown CBD to reduce sodium
currents in both wild-type and mutant Nav1.6 channels
(encoded by SCN8A, whose mutations are associated with
a severe epileptic encephalopathy).28 The overall inhibitory
effect of CBD on VGSC might contribute to its anti-
convulsant properties.
Another class of molecules, namely transient receptor
potential (TRP) cation channels, appears to be involved in
CBD signaling. More specifically, TRP channels of vanilloid
type 1 (TRPV1), activated by heat and capsaicin, are sup-
posed to be phosphorylated in case of neuronal activation.9
CBD is a TRPV1 agonist and is thought to induce TRPV1
activation, dephosphorylation and consequent desensitiza-
tion, which would decrease calcium levels and neuronal
excitability.17,23 TRP channel of ankyrin type 1 (TRPA1),
that often co-localizes with TRPV1 and is physiologically
activated bymenthol and cold, might also be a CBD target, as
well as TRP subfamily melastatin type 8 (TRPM8), on which
CBD acts as an antagonist.9,22
Finally, CBD is supposed to influence calcium modula-
tion through its action on VGCC, in particular of T- and
L-type, and on mitochondrial Na+/Ca2+ exchange.17
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Mitochondria might be otherwise involved in CBD signal-
ing, considering that the voltage-dependent anion-selective
channel protein 1 (VDCA1), located on the outer mito-
chondrial membrane, is antagonized by CBD.22
Several other molecules, including ion channels, recep-
tors and enzymes, have been identified as potential targets for
CBD, although their specific relevance in determining its
pharmacological effects is yet to be clarified. For instance,
CBD is an allosteric modulator, either positive or negative, of
α3 glycine receptors and μ/δ opioid receptors (which could
contribute to its analgesic properties), α1 adrenoreceptors and
Dopamine 2 (D2) receptors.22,23 Moreover, CBD could influ-
ence endocannabinoid signaling by modulating (in either
way) fatty acid amide hydrolase (FAHH), the enzyme
responsible for AEA metabolism.22
The anti-inflammatory properties of CBD might be
related to manifold mechanisms, including the mobiliza-
tion of arachidonic acid and the regulation of its metabo-
lite synthesis, namely leukotrienes, thromboxanes and
prostaglandins (although conflicting evidence is available
at present); the reduction of nitrous oxide (NO) thanks to
the inhibition of its inducible synthase (iNOS), and the
modulation of cytokine levels.22 Moreover, CBD has well-
known anti-oxidant properties: in fact, recent studies sug-
gest that it might induce the synthesis of reactive oxygen
species (ROS) in tumoral cells, which could partly justify
its anti-carcinogenic potential.15,22 As to that, gene tran-
scription modulation via agonism on peroxisome prolif-
erator-activator receptor γ (PPARγ) might also play a role.
Finally, CBD has been demonstrated to influence neutro-
phil chemotaxis29 and interact with microglia.30 Microglial
lamellipodia express CB2 receptors, and endocannabinoids,
in particular 2-AG, which are produced in case of inflamma-
tion, have been shown to active microglia cells through CB2,
inducing microglia migration towards the inflammation site.
CBD might be able to antagonize such mechanism, thus
exerting an anti-inflammatory effect.
Pharmacokinetic Properties of Oral
CBD
Considering that the recently approved CBD pharmaceu-
tical preparation consists of an oral solution (≥98% pure
CBD solubilized in sesame seed oil with additive sucralose
and strawberry flavoring, containing CBD 100 mg/mL),31
only this type of formulation will be taken into considera-
tion in the following discussion.
CBD has a complex and rather unfavorable PK profile,
which is greatly influenced by fasting/fed status and is prone to
develop various (and sometimes clinically relevant) drug–drug
interactions. Given its lipophilic nature, it has rather slow oral
absorption and a large volume of distribution (20,963 L to
42,849 L in healthy subjects), due to extensive distribution into
tissues. Its estimated plasma protein binding is about 94%.23
A pharmacokinetic Phase I, placebo-controlled trial performed
on healthy volunteers and comparing single ascending dose
(SAD) (1500, 3000, 4500 and 6000 mg) with multiple dose
(MD) (750 or 1500 mg/die BID for 7 days), found similar
times of peak concentration (tmax 3.5–5 h versus 3 h).
32 Steady
state was reached after 2 days in the MD arm, and a period
effect, with some degree of accumulation, was also documen-
ted. In the same study, exposure (area under the concentration–
time curve, AUC) to CBD showed a less than proportional
increase in the SAD arm of the protocol, which suggested
a change in bioavailability possibly due to a solubility-related
decrease in the absorption rate.32 Although this finding was
not confirmed in the MD group, studies on chronically treated
patients, with a daily dose ranging from 5 to 20mg/kg/d, led to
the same conclusion, as indicated in Epidiolex® prescribing
information.31,32
Bioavailability of orally administered CBD is estimated
at around 6%, probably as a result of poor gastrointestinal
absorption and high first-pass metabolism.23 As already
anticipated, food can dramatically influence CBD bioavail-
ability: indeed, in the above-mentioned Phase I trial, taking
a highly fat-containing meal within 20 mins of drug admin-
istration determined a more than 4-fold increase in exposure
to CBD, whereas tmax and terminal elimination half-life
(t1/2, z) were unchanged.
32 Such remarkable influence of
feeding status was further demonstrated in 8 epileptic
patients by Birnbaum and coworkers, who tested
a solid formulation (soft gelatinous capsules) of CBD
(200–300 mg) in order to avoid drawbacks related to liquid
preparations.33 In this study, the effect of a high-fat meal
(840–860 calories, 500–600 of which from fat) consisted in
a 14-fold increase of CBD maximal plasma concentration
(Cmax), that is a much higher rise than previously detected in
healthy volunteers taking CBD oil.33 Moreover, both tmax
(2.4 h vs 3.2 h) and t1/2 (24.3 h vs 38.9 h) were shorter
during fed status compared with fasting. Various mechan-
isms might justify the dramatic effect of food on CBD
bioavailability, including increased bile salt excretion and
prolonged gastric transit time due to fed status, with con-
sequent higher dissolution and absorption of lipophilic
compounds.32,33
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CBD is extensively metabolized in the liver, mainly by
cytochrome P450 (CYP) 3A4 and 2C19, which catalyze its
hydroxylation (to the active 7-OH-CBD) and further oxida-
tion, and are strongly inhibited by CBD itself. To a lesser
extent, CYP2C9, 1A1, 1A2 and 2D6 are also involved,
along with UDP-glucuronosyl-transferases (UGT) 1A9,
1A7, 2B7.22 The prominent metabolite is 7-COOH-CBD,
an inactive compound whose serum concentrations greatly
exceed (up to 47 times) those of the parent drug.
Elimination of CBD (33% of which is unchanged) is almost
exclusively via feces, and follows a biphasic pattern, with
an initial t 1/2 of 6 h, and a later terminal half-life of 24 h,
due to the slow release of the drug from the tissues where it
rapidly distributes after absorption.34
Given its extensive liver metabolism, it does not come
as a surprise that CBD PK profile is considerably influenced
by hepatic function. A recent phase I, open-label, parallel-
group study was performed on 22 subjects with hepatic
impairment from mild to severe (according to the Child-
Pugh score) receiving a single 200-mg dose of CBD, with
blood samples being collected pre-dose and over the fol-
lowing 48 h.35 A slight increase in exposure parameters was
observed in mildly impaired subjects, whereas the rise was
significant in moderately and severely impaired partici-
pants. Moreover, t1/2 was prolonged in affected subjects in
accordance with clearance reduction. All CBD metabolites
showed a comparable increase except for 7-COOH-CBD,
the most abundant one, which was the lowest in subjects
with severe hepatic dysfunction, pointing to a reduced liver
metabolic capacity.35 Based on these findings, a dose
adjustment should be always considered in patients with
hepatic dysfunction.
Finally, considering the prominent use (and exclusive
current indication) of CBD in childhood-onset drug-
resistant epilepsy (DRE), its pharmacokinetics has been
also evaluated in few pediatric populations. In the multi-
center, randomized, placebo-controlled, dose-finding trial
by Devinsky et al (GWPCARE1 part A), 34 DS patients
aged 4–10 years received CBD at 5, 10 or 20 mg/kg/day
BID for 3 weeks (starting from 1.25 mg/kg/day, with a 2.5
or 5 mg/kg increase every other day), followed by 10-day
tapering.36 The study documented a remarkable inter-
individual variability in the exposure parameters of CBD
(% Coefficient of variation (CV) 20–120%) and, even
more so, of its metabolites (%CV 57–1570%), although
the possible determinants (eg, interactions with other
AEDs) were not properly investigated. Exposure to both
CBD and its analytes showed a dose-proportional increase.
In the open-label INS011-14-029 study, a 99.5% pure
synthetic oral formulation of CBD was administered to
61 subjects aged 1 to 17 years suffering from DRE, as
both a single dose (5, 10 or 20 mg/kg on day 1, followed
by a preset volume of water or clear liquid) and a multiple
ascending dose (MAD) (10, 20 or 40 mg/kg BID, from day
4 to day 10).37 During the MAD phase, the median tmax
was 2–3 h, independent of the dose, and the steady state
was reached between 2 and 6 days. Apart from confirming
the high inter-subject variability and the dose-proportional
increase in exposure parameters, the authors of this trial
found that infants had lower CBD concentrations com-
pared with children and adolescents, regardless of the
administered dose.37
Pharmacological Interactions
Between CBD and Other AEDs
CBD interaction with Clobazam (CLB) is widely acknowl-
edged and might be particularly relevant in clinical practice
since both medications are commonly used in the treatment
of epileptic encephalopathies such as DS. CLB is metabo-
lized by CYP3A4 and CYP2C19 into N-desmethylclobazam
(norclobazam, nCLB), a compound that is 20–100% as
potent as the parent drug, and is further converted by
CYP2C19 into inactive metabolites.38 As first demonstrated
by Geffrey et al in 13 pediatric DRE patients treated with
CLB (0.18–2.24 mg/kg/day), the introduction of CBD
(titrated over 4 weeks up to 25 mg/kg/day) was associated
with a non-significant mean increase (60±80%) of CLB
levels, whereas concomitant nCLB concentrations rose by
500±300%.38 Such remarkable findings might be justified by
the strong inhibition exerted by CBD on CYP2C19. In 10 out
of 13 subjects, CLB doses were lowered by the investigators,
with a reported benefit on side effects (likely related to CLB),
although nCLB serum levels did not parallel the parent drug
decrease. In order to further assess the interactions between
these two medications, a Phase III RCTwas later performed
on 20 epileptic adult subjects on a stable dose of CLB,
receiving either CBD 20 mg/kg/day or placebo (4:1).39
Although complete results have not been published yet,
a remarkable increase in nCLB exposure parameters in the
CBD group, despite steady CLB concentrations, was con-
firmed by the investigators, in accordance with previous
results. Furthermore, while Geffrey and coworkers ruled
out any significant influence of CLB and its metabolites on
cannabidiol,38 Morrison and colleagues found that a 21-day
treatment with CLB 5 mg BID produced a slight increase in
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CBD and, more remarkable, in 7-OH-CBD levels, suggest-
ing a possible inhibition of UGTs and other minor CYPs.40
Most interestingly, beside the pharmacokinetic interference,
a pharmacodynamic interaction between CBD and CLB has
been also hypothesized based on preclinical evidence.
Indeed, a recent study on a mouse model of DS demonstrated
that a combination of CLB and CBD 100 mg/kg (endowed
with intrinsic anti-convulsant properties) was more protec-
tive against hyperthermia-induced seizures than either drug
alone.41 Conversely, the same effect was not observed when
adding CBD at a lower dose (12 mg/kg), although this was
proved to increase CLB and nCLB serum concentrations.
These findings suggested a pharmacodynamic (as well as
pharmacokinetic) interaction between CBD and CLB,
which the authors attributed to their action as positive allos-
teric modulators of GABAA receptors, in accordance with
other in vitro experiments.25,26 Unfortunately, the study was
unable to demonstrate a synergistic effect between CBD
and CLB.
As far as other AEDs are concerned, in the above-
mentioned phase I, open-label trial on healthy volunteers
by Morrison and coworkers, the authors investigated the
possible interactions between CBD (750 mg BID), valpro-
ate (VPA) (500 mg BID) and stiripentol (750 mg BID).40
The serum concentrations of neither VPA nor CBD changed
when administered in combination. As to stiripentol,42 its
exposure parameters rose by 28–55%, likely due to
CYP2C19 inhibition by CBD. More importantly, since stir-
ipentol is itself a strong inhibitor of CYP2C19, CYP2D6
and CYP3A4, it is supposed to prevent CBD-mediated
increase in nCLB levels, by “neutralizing” its effect on
CYP2C19 (whose stiripentol-dependent inhibition would
be already maximal at the time of CBD introduction).23 In
an open-label trial by Gaston and coworkers, CBD appeared
to affect the exposure to other AEDs as well: in particular,
a linear increase in the serum levels of topiramate (TPM)
and rufinamide (RFD) (in both adult and pediatric patients),
eslicarbazepine (ESL) and zonisamide (ZNS) (in adults
alone) was documented.43 However, further controlled
trials are warranted to confirm the significance of these
findings. Finally, in a recent small study on 5 adult DRE
patients, the introduction of CBD (up to 50 mg/kg/day) was
associated with a 95–280% increase in brivaracetam plasma
levels, although the possible mechanisms underlying such
interaction are still elusive.44 The effects of CBD on other
AEDs are shown in Table 1.
Effectiveness of CBD in DS and
LGS: Findings from RCTs
The effectiveness of CBD as anti-epileptic medication was
firstly investigated in 4 randomized, placebo-controlled
clinical trials performed from 1978 to 1990 on overall
48 adult patients with DRE (including 12 mentally impaired
institutionalized subjects).45–48 Although in half of the stu-
dies, a proportion of patients receiving the active treatment
(CBD 200–300 mg/day) reported some clinical benefit, the
relevance of these findings was affected by several metho-
dological flaws, such as small sample size, short follow-up,
lack of clinical details (including baseline seizure frequency
and severity), and insufficient information about randomi-
zation and blinding. Over the years, numerous papers,
mainly case reports, retrospective studies and open-label
Table 1 Interactions Between CBD and Other AEDs
Interacting AED Effect of DDI on Other AEDs Nature of
Interaction
Possible Underlying Mechanisms
PK PD
CLB Non significant ↑[CLB]PL (60%±80%); ↑↑↑[nCLB]PL (500%±300%) + (+) CBD-mediated inhibition of CYP2C19
Stiripentol ↑[Stiripentol]PL (28–55%) + CBD-mediated inhibition of CYP2C19
VPA Increased risk of ↑ transaminase levels and ↓PLTs - + Unknown
TPM ↑[TPM]PL (adults and children) + CBD-mediated inhibition of CYP2C19
RFD ↑[RFD]PL (adults and children) (+) Unknown
ESL ↑[ESL]PL (adults) (+) Unknown
ZNS ↑[ZNS]PL (adults) + CBD-mediated inhibition of CYP3A4
BRV ↑[BRV]PL (95–280%) (+) Unknown
Notes: The table shows only the effects of CBD on other AEDs (not vice versa). Possible (not properly demonstrated) interactions are indicated in brackets (). []PL:
plasmatic concentrations; ↑: increase; ↑↑↑: marked increase; ↓: decrease.
Abbreviations: AED, antiepileptic drug; BRV, Brivaracetam; CBD, cannabidiol; CLB, Clobazam; DDI, drug–drug interaction; ESL, Eslicarbazepine; nCLB, Norclobazam; PD,
pharmacodynamics; PK, pharmacokinetics; PLTs, platelets; RFD, Rufinamide; TPM, Topiramate; VPA, Valproic Acid; ZNS, Zonisamide.
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trials, dealt with the use of cannabis-containing medical
products in epileptic patients. However, considering the
low quality of these studies and the heterogeneity of the
investigational compounds, the following discussion will be
mainly focused on pivotal RCTs leading to CBD license for
the treatment of epileptic encephalopathies.
The regulatory agencies’ approval of CBD use in patients
suffering from DS was granted based on the findings of
a Phase II, randomized, double-blind, placebo-controlled
trial performed on 120 DS subjects aged 2–18 years (mean
age 9.8 years) with ≥4 convulsive seizures per month
(GWPCARE1 part B).49 The study design consisted in
a 4-week baseline period, followed by 2-week titration,
12-week maintenance and 10-day tapering. Patients were
randomized in a 1:1 ratio to either CBD 20 mg/kg/day BID
or placebo. The maximal dose of 20 mg/kg/day was recom-
mended based on the safety and PK data from GWPCARE 1
part A study.36 The primary endpoint was the percentage
change in convulsive seizure frequency per 28 days during
the entire treatment period compared with the 4-week base-
line, whereas the responder rate (ie, proportion of subjects
achieving ≥50% decrease in convulsive seizures) and the
reduction in the frequency of all seizures and nonconvulsive
ones were considered as secondary endpoints, along with
sleep quality, Caregiver Global Impression of Change
(CGIC), etc. CBD group showed a median change in con-
vulsive seizure frequency of −38.9% (from a median of 12.4
seizures/month at baseline to 5.9) compared with −13.3%
(from 14.9 to 14.1) in the placebo group, resulting in the
adjusted median difference of −22.8% (p=0.01). The most
notable reduction in seizure frequency was documented
within the first month of the maintenance period. Total sei-
zures per month decreased by 28.6% in patients on CBD
compared with 9% in those receiving placebo, with an
adjusted median difference of around 19% (p=0.03).
However, the responder rate (43% vs 27% in CBD and
placebo group, respectively, p=0.08) did not support the
superiority of the active drug over placebo, neither did the
reduction in nonconvulsive seizures alone (p=0.88). Such
findings might suggest that CBD is effective specifically in
convulsive seizures; still, the count of nonconvulsive ones
could be unreliable, and the study itself could be underpow-
ered to detect differences in the frequency of this seizure
type.50 However, the positive global impact of CBD treat-
ment was confirmed by the documented changes in the CGIC
scale, showing an improvement in 62% of children receiving
active treatment versus 34% of those taking placebo
(p=0.02). Another phase III RCT (GWPCARE2) compared
the effectiveness and tolerability of CBD 10 and
20 mg/kg/day with placebo in a population of children and
young adults diagnosed with DS.51 One-hundred-ninety-
eight patients from 38 worldwide sites were randomly
assigned in a 2:2:1:1 ratio to receive the active compound
(66 and 67 in 10 and 20 mg/kg/day groups, respectively) or
placebo (overall 65 subjects) for 14 weeks (2-week titration
and 12-week maintenance). Recently released preliminary
data showed a significantly higher responder rate in both
treatment arms (43.9% and 49.3% in 10 and 20 mg/kg/day
groups, respectively) compared with placebo (26.2%).
Similarly, remarkable differences favoring CBD over pla-
cebo were documented in the frequency change of both
convulsive (−48.7% and −45.7% vs −26.9%) and total sei-
zures (−56.4% and −47.3% vs −29.7%).
Apart from DS, CBD is also currently licensed for the
treatment of LGS. Two Phase III, randomized, double-blind,
placebo-controlled trials demonstrated CBD effectiveness and
safety as an adjunctive medication in pediatric and adult LGS
subjects.52,53 A total of 396 patients (225 and 171, respec-
tively), aged 2–55 years, with at least two generalized seizure
types over the last 6 months and 2 drop seizures over the
4-week baseline period, were enrolled. The first study
(GWPCARE3) compared CBD 10 mg/kg/day, CBD
20 mg/kg/day and placebo (with 73, 76 and 76 patients ran-
domly allocated in a 2:2:1:1 ratio), whereas in GWPCARE4
trial the active treatment consisted in CBD 20 mg/kg alone
(administered to 86 out of 171 patients). Both studies mainly
focused on CBD effectiveness on drop seizures, whose med-
ian monthly frequency at baseline was 85 and 73.8, respec-
tively. In GWPCARE3 trial, the percentage change in 28-day
frequency of drop seizures was significantly higher in both
treatment arms (−37.2% in CBD 10 and −41.9% in CBD 20)
compared with placebo (−17.2%), with an estimated median
difference of 19.2% for CBD 10 (p=0.002) and 21.6% for
CBD 20 (p=0.005). These findings were further confirmed by
the GWPCARE4 study, where the reduction in drop seizure
frequency was significantly superior in the treated patients
than in those receiving placebo (−43.9% vs −21.8%, with an
estimated median difference of −17.21%, p=0.0135).
Similarly, significant responder rates for drop seizures were
also found, regardless of dose (GWPCARE3: 36% in CBD 10,
39% in CBD 20, 14% in placebo, p=0.003 and p<0.001,
respectively; GWPCARE4: 43.9% in CBD group vs 21.8%
in placebo, p=0.0043). The clinical benefit on drop seizures
appeared to be persistent over the entire 12-week maintenance
period. Interestingly, CBD proved effective on non-drop sei-
zures as well: in particular, in the dose comparing trial, the
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estimated median difference with placebo was −28.3% in
CBD 10 and −22.4% in CBD 20 (although p-values were
not calculated), whereas it amounted to −26.1% (p=0.0044)
in favor of patients receiving CBD in GWPCARE4 study.
Similar trends were also observed in “total seizures”, support-
ing CBD effectiveness in treating all seizure types. In a recent
meta-analysis gathering data from both RCTs on LGS,54 no
dose–response correlation was found due to insufficient data.
However, seizure freedom from drop seizures during the
maintenance phase appeared more likely in patients on CBD
20 mg/kg/die (Risk Ratio 6.59), although it did not reach
statistical significance.
Most patients participating in the above-illustrated RCTs
were enrolled in an open-label extension (OLE) study
(GWPCARE5), including overall 630 subjects (264 with DS
and 366 with LGS) treated with adjunctive CBD (maximal
dose 30 mg/kg/day) for 1–3 years, with 12-week follow-up
visits.55,56 During the interim analysis period (after data cut in
November 2016) CBD was discontinued by 75 DS patients
and 67 LGS subjects (corresponding to a withdrawal rate of
28% and 18%, respectively), mainly due to adverse events
(AEs) and parent/patient consent withdrawal. In the DS group,
the responder rate was about 40% at each visit window, the
reduction in convulsive seizure frequency in the first trimester
was 37.5% and persisted throughout 48 weeks, whereas the
frequency of all seizures decreased by 39–50%.53 Five sub-
jects were free from convulsive seizures during their last
12 weeks. In the LGS population, half of the patients (range
49.2–54.4%) had a ≥50% improvement in drop seizure
frequency.56 Moreover, at first follow-up visit, the median
percentage change in seizure frequency was −48.2% for drop
seizures and −47.7% for all seizure types. The clinical benefit
appeared to persist in time, and no tolerance was observed.
A remarkable proportion of participants to pivotal RCTs
(and OLE study as well) were taking concomitant CLB
(66% in GWPCARE1B, 49% in GWPCARE3, 48% in
GWPCARE4, 58% in GWPCARE5), with possible clini-
cally relevant interactions. Indeed, in the first open-label
trial on CBD as an add-on medication in a heterogeneous
population of childhood-onset DRE, Devinsky and cow-
orkers found the responder rate (for motor seizures) to be
higher among subjects taking CLB (51%) compared with
the others (27%).57 Besides, the multiple logistic regression
analysis showed CLB to be the only independent predictor
of motor seizure frequency reduction. Unfortunately, data
on CLB and nCLB serum concentrations were not avail-
able. By pointing to the possible influence of CLB on
seizure outcome, these findings raised concerns about the
actual anti-convulsant efficacy of CBD alone.58,59 In fact,
a post-hoc analysis performed on LGS patients enrolled in
GWPCARE3/4 studies showed CBD to be more effective
than placebo regardless of CLB status.60 This conclusion is
in accordance with the results of a recent open-label, com-
passionate-use trial by Gaston and colleagues evaluating the
possible clinical impact of CLB and other “interfering”
AEDs (namely TPM, ESL, ZNS, RFD, based on
a previous study by the same authors), when administered
in combination with CBD.43,61 Seizure frequency and
severity appeared independent of concomitant treatments,
suggesting that relevant interferences were unlikely; never-
theless, these findings should be interpreted with caution
considering the intrinsic limitations of the study design.
An overview of the pivotal RCTs leading to CBD
license is illustrated in Figure 2.
CBDEffectiveness in Other Epileptic
Syndromes
Expanded access programs allowed several patients suffer-
ing from childhood-onset DRE other than DS and LGS to
receive CBD as an adjunctive treatment. Despite the current
dearth of solid evidence coming from high-quality studies,
this paragraph will provide a brief overview of a few spe-
cific epileptic syndromes where CBD might represent
a useful therapeutic option. Among them, TSC has been
the most extensively investigated so far and deserves
a special mention since CBD received Orphan Drug desig-
nation for TSC by both FDA and EMA. Eighteen subjects
with TSC diagnosis, aged 2–31 years, were enrolled in the
expanded assess trial by Hess and colleagues, and followed
for ≥6 months.62 The majority of them (14/18) also pre-
sented developmental delay. CBD was administered at an
initial dose of 5 mg/kg/day, with following 5 mg/week
titration up to 25 mg/kg/day: however, further increases to
maximal dose of 50 mg/kg/day were allowed for unsatis-
factory seizure control, without apparent safety issues.
Although only 8/18 subjects achieved a 12-month follow-
up, the overall mean seizure frequency showed a decreasing
trend over time, of different entity according to seizure
types: indeed, frequency reduction was more pronounced
for tonic-clonic seizures (−91.4%), infantile spasms (IS)
(−87.5%) and atonic seizures (−86.5%) compared with
focal ones; moreover, responder rate at 3 months was higher
for IS and atonic seizures (75% each). Among 10/18
patients taking concomitant CLB, 58.3% were responding
to treatment at 3 months, compared with 33.3% of the
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others. Besides, cognitive and behavioral improvements
were reported in 85.7% and 66.7% of cases, respectively.
The authors concluded that CBD might be a tolerable and
effective adjunctive treatment for TSC patients, in accor-
dance with preclinical evidence,26 with a possible specific
efficacy on IS. Nevertheless, given the open-label design of
the study, changes in concomitant AEDs were minimized
but not completely avoided for the first 3 months; moreover,
seizure aggravation was documented in as well as seven
patients at some point during the observation period. In the
wake of this study, a phase III RCT (GWPCARE6) was
performed on 224 TSC patients, aged 1–65 years (mean age
14 years), to evaluate the safety and efficacy of CBD
25mg/kg/day (75 patients) and CBD 50mg/kg/day (73 sub-
jects) versus placebo (76 cases) over a 16-week treatment
period (4-w titration and 12-w maintenance).63 Patients
concomitantly treated with oral mTOR inhibitors were
excluded. The primary endpoint was the change in overall
seizure frequency, but several secondary endpoints, includ-
ing changes in the number of different seizure types (focal
seizures with or without awareness impairment, focal to
bilateral tonic-clonic seizures, generalized seizures) and in
Insulin Growth Factor 1 (IGF1) serum levels were evalu-
ated as well. In May 2019, the manufacturer announced that
the study met the primary endpoint, with a seizure fre-
quency reduction significantly higher in both CBD 25
group (48.6%, p=0.0009) and CBD 50 group (47.5%,
p=0.0018) when compared with placebo (26.5%).64
Finally, Devinsky and coworkers analyzed data from
a subgroup of 55 patients diagnosed with specific epileptic
syndromes, namely CDKL5 deficiency disorder (20 sub-
jects), Aicardi syndrome (19 patients), Doose syndrome and
Dup15q syndrome (8 cases each), who received CBD
(>20 mg/kg) during the expanded access trial.65 The pooled
analysis showed a largely significant reduction in convul-
sive seizure monthly frequency at 12 weeks (from median
59.4 seizures/month at baseline to 22.5 at follow-up), which
was persistent over 48 weeks (without further improve-
ment). Accordingly, the responder rate for convulsive sei-
zures was 50% at 12 weeks and 57% at 48. As to retention,
five patients withdrew CBD by week 12, 10 by week 48,
and 15 by week 144 of extended follow-up, mainly for
unsatisfactory seizure control (9) or AEs (4). However,
further studies with better design are warranted before any
conclusion is drawn on CBD effectiveness as an adjunctive
medication for these difficult-to-treat syndromes.
Tolerability Profile of CBD
In the open-label trial by Devinsky and colleagues on the
compassionate use of CBD for pediatric and adult DRE
patients, 128/162 subjects (79%) reported side effects, the
most common being somnolence (25%), decreased appetite
(19%), diarrhea (19%), fatigue (13%) and convulsions
(11%).57 Moreover, 48 participants developed serious
adverse events (SAEs), which the investigators deemed to
be causally related to CBD in 20 cases (12%). Interestingly,
Figure 2 The figure shows the randomized, double-blind, placebo-controlled trials (followed by ongoing open-label extension studies) performed to evaluate CBD
effectiveness and tolerability in DS, LGS and TSC. The percentages shown in the figure indicate the responder rates, ie, the proportion of patients showing >50% seizure
reduction (for motor seizures in DS, drop seizures in LGS and convulsive ones in TSC) of CBD 20 mg/kg/day compared with placebo.
Abbreviations: DS, Dravet syndrome; LGS, Lennox-Gastaut syndrome; TSC, tuberous sclerosis complex.
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only 3% of patients withdrew CBD because of AEs, sug-
gesting that either treatment-related benefits outweighed
drawbacks, or that parents had too much hope in CBD
effectiveness to discontinue it due to tolerability issues. In
the safety, PK, dose-finding study on 34 DS subjects, treat-
ment-emergent AEs were reported in each arm, and led to
withdrawal in two subjects.49 Based on these results,
20 mg/kg/day was established as the maximal CBD dose
for future trials (despite higher doses, up to 50 mg/kg, were
used in both open-label studies and in the RCT on TSC
subjects, whose safety data are not yet available).
The recent meta-analysis by Lattanzi et al on overall 550
DS and LGS patients participating to three pivotal RCTs
showed that 11.1% subjects taking CBD discontinued treat-
ment, compared with 2.6% receiving placebo (p=0.003);
moreover, 8.9% of the actively treated population withdrew
because of AEs (versus 1.8% in the placebo group).50 Both
all-cause withdrawals and those due to AEs appeared sig-
nificantly more common among subjects taking CBD
20 mg/kg/day compared with CBD 10 mg/kg/day. AEs
were reported by a remarkable proportion of patients in
both CBD and placebo groups (87.9% and 72.2%, respec-
tively), in line with other AEDs in the same populations, but
they were mostly mild to moderate, and generally transient.
Besides, SAEs involved 60/323 treated patients (RR 2.61).
In accordance with previous findings from expanded access
programs, the most common treatment-emergent AEs were
somnolence (24.5%), appetite decrease (20.1%), diarrhea
(18.2%, which might be related to sesame vehicle),57 and
elevation in transaminase levels (16.1%). Moreover, the
authors confirmed the correlation between side effects and
CBD dose.38 In the LGS subgroup, transaminase level
increase was the most common cause of AE-related with-
drawal, although none patient met the criteria for drug-
induced liver injury.54 Elevation in transaminases was an
early finding (documented within the first 90 days in almost
all patients), it generally appeared transient, and resolved
spontaneously or after down-titration of either CBD or
another AED. Interestingly, the pooled analysis confirmed
that only patients taking concomitant VPA might develop
an increase in transaminase levels. Considering that phar-
macokinetic interferences between CBD and VPA (whose
serum concentrations were not affected by CBD concomi-
tant administration, nor vice versa) have been clearly ruled
out,40 a pharmacodynamic interaction between these two
compounds might be advocated to explain the higher risk of
hepatotoxicity in patients on combined therapy. As pre-
viously stated, somnolence was the most common
treatment-emergent AE in nearly all studies, and appeared
more likely in subjects receiving concomitant CLB: indeed,
over two thirds of LGS patients on CBD reporting somno-
lence were also taking CLB (66.7% and 69% in
GWPCARE3 and 4, respectively),52,63 and an even higher
percentage (81.8%) was documented among DS subjects
treated with CBD in the pivotal trial (GWPCARE1B).47
Accordingly, Geffrey and colleagues found that all AEs
(including somnolence and sedation) improved after CLB
down-titration, regardless of nCLB serum levels.37 It
should be mentioned that rashes have also been described
in epileptic patients receiving CBD (17.6% in the safety
trial on DS),36 as well as in healthy volunteers (11%, appar-
ently when the drug was not properly titrated and/or
stored).40 Finally, CBD did not appear to affect sleep qual-
ity, cognition and behavior, as expected based on its non-
intoxicating profile.50,66
Findings from open-label extension studies will add pre-
cious information about CBD long-term tolerability: data from
interim analysis showed a proportion of SAEs superior to 25%
in both DS and LGS population, among which SE was the
most common (11% and 7.1% in DS and LGS patients,
respectively), although it seldom led to CBD
discontinuation.65,66 AEs reported during the GWPCARE5
trial (interim analysis) are shown in Table 2.
Not Only CBD: A Glance at
Cannabidivarin
As previously stated, CBDV is the n-propyl analogue of
CBD, and it is being currently investigated as a therapeutic
option in both epilepsy and autism spectrum disorder. Its
anti-convulsant properties have been documented in several
animal models of acute seizures and SE, where it proved
widely effective (except for pilocarpine-induced SE).67
Like CBD, CBDV has little affinity for CB1 and CB2, and
like CBD it is considered a “multi-target” drug, known to
act as an agonist on TRPV1/2 and TRPA1 channels, and as
an antagonist on TRPM8 channels.68 It also inhibits DGLα,
involved in endocannabinoid synthesis. Interestingly,
a recent in vitro study also suggested that GABAA receptors
might be a target of CBDV, which was proved to reduce
GABA “run-down” at therapeutic doses.69 Nevertheless,
the exact mechanisms underlying CBDV anti-convulsant
properties are yet to be clarified.
CBDV is a highly liposoluble compound with a large VL
(32 L/kg), it is able to rapidly penetrate the blood-brain
barrier and has a poor oral bioavailability.70 A single
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phase I study on healthy volunteers evaluated the PK profile
of CBDVoral formulations (25, 75, 200, 400, 800 mg/day
over 5 days) and IV preparation (5-mg, single-dose).71 The
drug was well tolerated when administered in both routes,
and rapidly metabolized in the liver to 7-OH-CBDV and
7-COOH-CBDV, although the exact metabolic pathway is
still unknown. In the same study, exposure parameters
(Cmax and AUC) also showed a dose-proportional increase
(from 200 to 800 mg/day).
A recent phase II trial evaluated PK, safety (part A)
and effectiveness (part B) of a proprietary, plant-derived,
purified formulation of CBDV (GWP42006) in adult
patients with uncontrolled focal seizures. Part A included
34 subjects, randomized in a 4:1 ratio to receive CBDV
400 mg BID or placebo for a 14-day treatment period:
participants were divided into three parallel groups,
according to concomitant medications (inducer AEDs,
inhibitor AEDs and non-interfering AEDs).72 Apparently,
no differences in CBDV PK and safety were documented
among the three groups (unpublished data).73 On the other
hand, 162 subjects (mainly from Eastern Europe) were
enrolled in part B and randomly assigned to receive either
CBDV 800 mg/day or placebo for 8 weeks (2-week titra-
tion and 6-week maintenance), followed by 12-day
tapering.74 Although the study results have not been pub-
lished yet, in February 2018 the manufacturer announced
that the trial failed to meet its primary endpoint, ie, the
percentage change in focal seizure frequency from base-
line to the end of the maintenance period, which amounted
to −40% in both actively treated and placebo groups.75
However, the investigators reasonably pointed out that the
extent of clinical benefit in subjects taking placebo was
exceedingly high when compared with previous trials,
which perhaps is in line with the increasing trend in
placebo response recently observed in RCTs, that surely
represents a matter of concern for clinical research.
However, it cannot be ruled out that the use of a purified
compound might have influenced the outcome, as already
hypothesized concerning CBD-based medications.76 As to
tolerability, AEs were reported by a larger proportion of
actively treated patients compared with the placebo group
(73% versus 48%): most AEs were from mild to moderate
in severity, and SAE incidence was generally low (3.7%
and 1.2% in CBDV and placebo groups, respectively). In
light of these unsatisfactory results, future studies explor-
ing CBDV therapeutic potential in epilepsy should be
addressed to specific patient populations.
Future Prospects for Cannabinoid
Use in Epilepsy Treatment
In recent times, the anti-epileptic potentialities of canna-
bis-based medical products have been the focus of intense
clinical research as well as the object of overwhelming
media attention. After years of “haze”,77 solid evidence
supporting CBD effectiveness came from pivotal RCTs on
DS and LGS, that showed responder rates ranging from
36% to almost 50%, and a proportion of freedom from
convulsive/drop seizures around 5%, which are remark-
able outcomes considering the refractoriness observed in
epileptic encephalopathies. Although CBD was suffi-
ciently tolerable as to lead most parents/participants to
enroll in the OLE trials, the majority of treated subjects
reported AEs, mainly CNS symptoms and gastro-intestinal
Table 2 AEs Reported in the Open-Label Extension Study
(Interim Analysis)
DS
n=264
LGS
n=366
All-causality AEs, n (%) 246 (93.2) 337 (92.1)
AEs leading to withdrawal, n (%) 19 (7.2) 35 (9.6)
AEs reported in >10% of patients, n (%)
Diarrhea 91 (34.5) 98 (26.8)
Pyrexia 72 (27.3) 69 (18.3)
Decreased appetite 67 (25.4) 65 (17.8)
Somnolence 65 (24.6) 86 (23.5)
Nasopharyngitis 41 (15.5)
Convulsion 40 (15.2) 78 (21.3)
Vomiting 37 (14.0)
Upper respiratory tract infection 36 (13.6) 53 (14.5)
Status epilepticus 29 (11.0)
Fatigue 27 (10.2)
SAEs, n (%) 77 (29.2) 94 (25.7)
SAEs reported in >1% patients, n (%)
Status epilepticus 29 (11.0) 26 (7.1)
Convulsion 13 (4.9) 20 (5.5)
Pyrexia 10 (3.8)
Pneumonia 7 (2.7) 9 (2.5)
AST increased 5 (1.9) 6 (1.6)
ALT increased 6 (1.6)
Hepatic enzyme increased 4 (1.1)
Pneumonia aspiration 6 (1.6)
Dehydration 4 (1.5)
Influenza 4 (1.5)
GTCSs 4 (1.5)
Diarrhea 3 (1.1)
Note: Data from Devinsky et al55 and Thiele et al.56
Abbreviations: AE, adverse event; DS, Dravet syndrome; GTCSs, generalized
tonic-clonic seizures; LGS, Lennox-Gastaut syndrome; SAE, serious adverse event.
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disturbances (likely due to the vehicle); however, they
were from mild to moderate and generally transient.
Based on these findings, CBD could be rightfully consid-
ered a valid tool in the rather poor therapeutic armamen-
tarium of DS and LGS. Still, it is a medication, not
a panacea, and, as such, it is not devoid of risks, including
the potential for seizure aggravation. Neurologists should
keep that in mind when prescribing CBD, taking into
consideration its limited therapeutic indications, its possi-
ble side effects and, equally important, its remarkable
interactions with other AEDs. Moreover, findings from
real-world studies on larger populations will help us eval-
uate the real extent and duration of CBD clinical benefit
and its long-term tolerability.
As to future prospects, CBD might find novel clinical
applications, as it is currently being evaluated in other con-
ditions, including IS, Rett syndrome and Fragile
X syndrome, not to mention several neuropsychiatric dis-
eases such as schizophrenia and autism spectrum disorders.
Moreover, in order to maximize its therapeutic potential by
increasing bioavailability, formulations other than the com-
monly used oral preparations (eg, transdermal) are also being
tested. Finally, it is still an open question whether cannabis
extracts could actually be more effective and tolerable than
purified components, as recently suggested by a meta-
analysis on 11 studies and overall 670 subjects.76 The reason
for the hypothesized superiority of plant extracts over single
compounds could lie in the so-called “entourage effect”,78
a phenomenon first described in endocannabinoids and then
in pCBs, which refers to the synergistic action of both active
and inactive botanical molecules in cannabis plants. Indeed,
not only different pCBs can interact with each other (as
demonstrated by CBD antagonism with THC,79 and the
documented additive anti-convulsant actions of CBD and
CBDV),80 but also terpenoids, lipophilic molecules found
in cannabis plants and endowed of intrinsic pharmacological
actions, could play a role in potentiating pCB effects.
Overall, these considerations reflect the great complexity of
cannabis pharmacology, which requires extensive researches
to explore its real potentialities and to better define its indica-
tions in clinical practice.
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TRPV1, transient receptor potential channel of vanilloid type
1; TRPA1, transient receptor potential channel of ankyrine type
1; TRPM8, transient receptor potential melastatin type 8;
TPM, topiramate; TSC, tuberous sclerosis complex; UGT,
UDP-glucuronosyl-transferase; VDCA1, voltage-dependent
anion selective channel protein 1; VGCC, voltage-gated cal-
cium channels; VGSC, voltage-gated sodium channels; VPA,
valproic acid; ZNS, zonisamide.
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